Sensors and monitors for a physiological monitoring system having capability to indicate an accuracy of an estimated physiological condition. The sensor senses at least one physiological characteristic of a patient and is connectable to a monitor that estimates the physiological condition from signals detected by the sensor. The sensor includes a detector for detecting the signals from the patient which are indicative of the physiological characteristic. The sensor is associated with a memory configured to store data that defines at least one sensor signal specification boundary for the detected signals. The boundary is indicative of a quality of the signals and an accuracy of the physiological characteristic estimated from the signals by the monitor. The sensor further includes means for providing access to the memory to allow transmission of the data that defines the at least one sensor boundary to the monitor.

Method and circuit for indicating quality and accuracy of physiological measurements

Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes

Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

The present invention relates to methods for identifying inhibitors of the bitter taste response, and by methods of using such inhibitors to either block the perception of bitterness and/or promote the perception of a sweet taste. The inhibitors of the invention may be used as flavor enhancers in foods and pharmaceuticals. The methods of the invention may further be used to characterize the gustatory perception of novel tastants.

Inhibitors of the bitter taste response

2-Iminopyrrolidine derivatives represented by the general formula (I) or salts thereof: (I) wherein B is a benzene or pyridine ring, or the like; R101 to R103 are each hydrogen, halogeno, C1-6 alkyl, or the like; R5 is hydrogen, C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, or the like; R6 is hydrogen, C1-6 alkyl, C1-6 alkyloxycarbonyl, or the like; Y1 is a single bond, -CH2-, or the like; Y2 is a single bond, -CO-, or the like; and Ar is hydrogen, a group represented by the general formula (II): (II) (wherein R10 to R14 are each hydrogen, C1-6 alkyl, hydroxyl, C1-6 alkoxy, or the like, or R11 and R12 or R12 and R13 may be united to form a 5- to 8-membered heterocycle), or the like.

2-iminopyrrolidine derivatives

Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in combination with lactic acid generating bacteria Also provided are methods for treating animal diseases and syndromes using these compositions

Compositions for treating animal diseases and syndromes

A skin care or deodorant composition comprises phytic acid in the form of a salt with at least one metal ion preferably selected from sodium, potassium, calcium, and magnesium ions.

Skin care and deodorant compositions

PURPOSE: To produce a food composition for hypofunctional diseases. CONSTITUTION: A function-improving food material consisting of a composition containing 40±35wt.% oil and fat component containing at least one or more compounds of 15±10wt.% eicosapentaenoic acid (EPA), 15±10wt.% docosahesaenoic acid (DHA) and 20±15wt.% α-linolenic acid and 30±20wt.% protein and as necessary 10±5wt.% lecithin, and a semisolid or solid functional food containing the material. This food material is a functional food capable of enhancing safety and processability of DHA or EPA and continuously using as a processed food and being effective in arresting advance of hypofunctional diseases, particularly, senile diseases and mental diseases and improving these diseases. COPYRIGHT: (C)1994,JPO&Japio

Food composition for hypofunctional disease

Pharmaceutical compositions for oral administration used for the treatment and prevention of hyperlipemia, obesity and obesity-related diseases contain phytic acid or its salt as a pharmaceutically effective component.

Pharmaceutical compositions containing phytic acid or its salts

A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): (I) wherein R represents -CH2CH2COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137+/-84 (137 on average with a standard deviation of +/-3 sigma ); and having the following minimum constitutional unit: (O+E,fra 1/2+EE )3GeCH2CH2COOH and the following empirical formula: C6H10Ge2O7, a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.

Maillard reaction inhibitor

Remedies, preventives and functional diets for diabetic diseases, esp., diabetes, contain phytic acid or its salt or salts. The salt of phytic acid is a non-toxious metal salt, or a non-toxious salt with an organic base, a basic amino acid or an organic ester residue, and has a compositional form together with or separately from phytic acid.

Naohisa Ninomiya

Papers

Skin care and deodorant compositions

Food composition for hypofunctional disease

Pharmaceutical compositions containing phytic acid or its salts

Maillard reaction inhibitor

Remedies and preventives for diabetic diseases